DISCLAIMER AABPS is a non-profit, volunteer

D
I
S
C
L
A
I
M
E
R
AABPS is a non-profit, volunteer-driven, professional organization.
Information published in this magazine has been provided by individuals and
organizations.
AABPS is not responsible for the accuracy of the presented information.
2
AABPS
CONVENTION
2014
CONVENTION
Buffalo Niagara Marriott in Amherst, New York
August 8 & 9, 2014 (Friday & Saturday)
© All rights reserved by the authorities of American Association of
Bangladeshi Pharmaceutical Scientists, AABPS.
No part of this printed material can be reproduced in any means
without publisher’s permission.
Published in Auguest, 2014. Printed in the USA.
Please visit www.aabps.org
for the electronic version of this brochure.
Graphics Design: Mamoon Rashid, PhD
3
PRESIDENT
PEOPLE’S REPUBLIC OF BANGLADESH
DHAKA
5 May 2014
It gives me immense pleasure to learn that the American Association of
Bangladeshi Pharmaceutical Scientists (AABPS) is going to organize its
2nd Convocation at the Buffalo Niagara Marriott in Amherst, New York,
USA on August 8-9, 2014. On the occasion of this august convention, I
convey my warmest greetings and felicitations to the erudite members of
AABPS.
Ensuring access to quality medicine is one of the most cherished goals of
the Government of Bangladesh. It is on this principle that the Government
always motivates and supports the pharmaceutical industry in Bangladesh
to flourish this sector to a great extent. I have been informed that today
pharmaceutical industry is one of the most thrust and rich sectors of the
country and it is making praiseworthy contributions to the country’s
socio-economic developmet by fulfilling about 97 per cent of the total
domestic demand of medicine as well as by earning valuable foreign
currencies through exporting medicine around the world. I am happy to
note that the AABPS is working at global arena with reputation and I
hope that this organization would extend its expertise in pharmaceutical
developments, manufacturing, regulatory issues and pharmacy education,
and thereby eventually help Bangladesh capturing more global market. I
also encourage its members to work side by side with similar professional
organizations in the healthcare, pharmaceutical industry and academia in
Bangladesh.
I wish the 2nd Convocation of the American Association of Bangladeshi
Pharmaceutical Scientists a great success.
Khoda Hafez. May Bangladesh Live Forever.
Md. Abdul Hamid
4
CONVENTION
Welcome Note
AABPS Executive Committee
and Organizing Chairs
On behalf of American Association of Bangladeshi Pharmaceutical Scientists (AABPS), we sincerely and
warm heartedly welcome our members, guests, volunteers, and family members to the 2nd AABPS Convention in Amherst, New York. We are extremely happy that you are attending the 2nd convention in this
internationally acclaimed wonderful and historic Niagara Falls Area. It is truly an exciting moment for
all of us to meet and exchange ideas with many members representing the field of Pharmacy and Pharmaceutical Profession from different parts of our globe. It is our continuation of journey for establishing
a strong professional organization and the legacy of our successful 1st AABPS convention last year.
It is our firm conviction that the commitment and dedication of our members have made AABPS
evolve into a highly visible professional organization. We can proudly announce that AABPS is not
only helping members in their professional enrichment, collaboration, leadership, and graduate/professional education, but is also an advocacy-group and resource for Bangladeshi-American pharmaceutical
professionals. AABPS now provides a common platform for its members to work with other professional
organizations in the health care, pharmacy, pharmaceutical industry, regulatory agency and academic
institution to advance human health and their well-being. We understand we have a long road ahead
but we are confident that our members with their excellent knowledge, expertise, vigor and courage, will
establish AABPS as an effective professional organization. The field of Pharmacy and Pharmaceuticals
is having a greater role in the overall global healthcare. We are confident, AABPS members with their advanced knowledge, expertise and innovations, will contribute to their fullest capability for a better global
healthcare.
The theme of this year’s convention is “Advancing Knowledge & Fostering Collaboration”. Through this
convention, AABPS would like to advance its mission and goals, fortify professional knowledge, help
young professionals succeed in their career and increase further the visibility of AABPS in the national
and international arena. We are happy to see your overwhelming enthusiasm, participation and attendance in this convention.
The beautiful venue, great speakers, rich professional programs, fine hospitality and excellent cultural
programs are a result of the extraordinary efforts of all the Convention Committees. The determination
of chairs, co-chairs and members of these committees to take their responsibilities and challenges are
highly commendable. We are honored to recognize all the convention Committee members listed in the
convention magazine and volunteers for their diligent work in organizing this 2nd convention. Without
their vision and dedication this convention would not have been possible. We would like to specially acknowledge and thank our families for their great sacrifice, strong support and enormous patience during
the countless hours for organizing this convention.
We hope for a very successful convention, and an exciting and wonderful time for you and your family at
Amherst and Niagara Falls Area. Best Wishes.
Muhammad Delwar Hussain, Ph.D.
Mohammad Hossain, Ph.D.
5
6
CONVENTION
Convention Committee
AABPS 2014
REGISTRATION COMMITTEE
»»Saleh Hussain (Chair)
»»Milad Khan (Co-Chair)
»»Shahid Alam
»»Anwar Hussain
»»Arshad Jamil
»»Mahiuddin Talukdar
FUND RAISING COMMITTEE
»»Mohammed Shameem (Chair)
»»Naushad Islam (Co-Chair)
»»Zahur Islam
SITE SELECTION COMMITTEE
»»Ashraf Khan (Chair)
»»Mohammad Hossain (Co-Chair)
»»Nahid Zaman
»»Saleh Hussain
»»Muhammad Delwar Hussain
CONSTITUTION COMMITTEE
»»Zahur Islam (Chair)
»»Jamil Habib (Co-Chair)
»»Mohammad Rahman
»»Muhammad Delwar Hussain
»»Mohammad Hossain
PUBLICITY COMMITTEE
»»Mamoon Rashid (Chair)
»»Ahmad Abdullah (Co-Chair)
»»Milad Khan
»»Mohammad Hossain
»»Devabrata Mondal
CULTURAL COMMITTEE
»»Shahid Khandker (Chair)
»»Ahmad Abdullah (Co-Chair)
»»Rajib Paul
»»Shamsul Hoque (Tagor)
»»Mortuza Bakshi
SOUVENIR COMMITTEE
»»Muhammad Delwar Hussain (Chair)
»»Zahur Islam (Co-chair)
»»Mohammad Hossain
»»Nasir Uddin
SPEAKER & AWARD COMMITTEE
»»Jamil Habib (Chair)
»»Jabed Seraj (Co-Chair)
»»Murad Husain
»»Muhammad Delwar Hussain
»»Mohammad Hossain
GRADUATE STUDENT COMMITTEE
»»Nahid Kamal (Chair)
»»Nahid Zaman (Co-Chair)
»»Rashedul Islam
»»Saifur Rahman
»»Tanvirul Hye
»»Ehtesham Reza
7
Sponsors of the Convention
Platinum
Sponsors
Graduate Student
Travel Award Sponsors
»»Dr. Swapan Kumar Das
»»Emcure Pharma
»»Mr. Abdul Muktadir
»»Mr. Salim Joardar
»»Solco Healthcare
»»Square Pharmaceuticals Ltd.
Gold
Sponsors
»»Aristo Pharma
»»Dr. Mohammed Shameem
»»Dr. Rajib Paul
»»Dr. Mohammed Shameem
»»Dr. Saleh Hussain
»»Mr. Abdul Muktadir
»»Mr. Ahmad Abdullah
»»Mr. Mominul Islam
Souvenir
Sponsor
»»Dr. Zahur Islam
diamond
Sponsor
»»Dr. Zahur Islam
With Best Compliments from
8
Program Outline
Friday, August 8th
EVENING SESSION 5:00 PM – 5:30 PM
5:30 PM – 8:00 PM 5:30 PM – 5:45 PM
CONVENTION
Advancing Knowledge & Fostering Collaboration
Ballroom 5
Program Committee Meeting
Registration (Ballroom 5 Lobby)
Reception and Welcome Address
Mohammad Hossain, PhD
5:45 PM – 6:05 PM
“Development of Bangladesh Pharma Sector and Its Potential as a Global Generic HUB”
Mollick Mahmood Hossain, MPharm
Managing Director, Novelta Bestway Pharmaceuticals, Bangladesh
Ahmad Abdullah, MPharm (Moderator)
6:05 PM – 6:25 PM
“Mass Spectroscopy as a Detection Technique Gaining Popularity in
Analytical Assessment”
Arshad Jamil, MPharm, MS, Senior Research Scientist, Emcure Pharmaceuticals
Mohammad Hossain, PhD (Moderator)
6:30 PM – 8:00 PM
Dinner (Sponsored by and Complements of AABPS) and Networking
8:00 PM – 8:55 PM
“Inspiring Our Youth” - An Interactive Session with Our Youth & Family
Shahid Rahman, Founder & President,
Inspiring South Asian Youth (ISAY) Foundation
Zahur Islam, PhD (Moderator)
9:00 PM
Visit Niagara Falls at Night (Private arrangement)
th
Saturday,
August 9
MORNING SESSION
7:30 AM – 6:00 PM
7:45 AM – 8:45 AM
8:30 AM – 9:30 AM
9:30 AM – 9:45 AM
Ballroom 5
Registration (Ballroom 5 Lobby)
Breakfast and Networking (Poster Viewing)
Sunrise Session: “Applications of Statistical Concepts in Pharmaceutical Sciences”
Mahmudul Huq Khan, PhD, Novartis Pharmaceuticals
Zahur Islam, PhD (Moderator)
Opening Remarks
Muhammad Delwar Hussain, PhD
9:45 AM – 11:45 AM: Plenary Session: “Current Trends in Drug Development:
Clinical, Manufacturing and Regulatory Strategies”
9:45 AM – 10:15 AM: “TAS-102: A case study in the Phase I through III clinical development of
anti-cancer compound”
Fabio Benedetti, MD, Senior VP Chief Medical Officer, Taiho Pharma, USA
Muhammad Jamil Habib, PhD (Moderator)
10:15 AM – 10:45 AM Mid-Morning Refreshment and Networking (Poster Viewing)
10:45 AM– 11:15 AM: “Bangladesh Pharmaceutical Industries and its contribution to the health care”
Tapan Chowdhury, Managing Director, Square Pharmaceuticals Ltd., Bangladesh
Naushad Islam, MS (Moderator)
9
Program Outline
11:15 AM – 11:45 PM “Challenges and Opportunities of Professional Practice in North America”
Ahmad Abdullah, MPharm, Proprietor, Shoppers Drug Mart, Scarborough, Ontario
Saleh Hussain, PhD (Moderator)
12:00 PM– 1:00 PM Lunch and Networking (Poster Viewing)
AFTERNOON SESSION Ballroom 5
1:00 PM – 2:00 PM Focus Group Discussion: “Advancing Knowledge Through Collaboration”
Group I (Analytical and Formulation Development)
Moderators: Enamul Kabir, MS & Shah Rashid, MS
Group II (Biologics)
Moderators: Muhammad Delwar Hussain, & Milad Khan, MS
Group III (Clinical Research)
Moderators: Jabed Seraj, MD, PhD & Mohammad Hossain, PhD
Group IV (Pharmacy Practice):
Moderators: Swapan Kumar Das, PharmD & Ahmad Abdullah, MPharm
Group V (Regulatory Affairs)
Moderators: Naushad Islam, MS & Fakrul Sayeed, PhD
Group VI (Generic Product):
Moderators: Anwar Hossain, PhD & Sharif Ahmed, MS
2:00 PM – 2:45 PM
Focus Group Panel Updates
2:50 PM – 3:30 PM Graduate Student Forum: “Sailing to Success in Education, Research and Career”
Moderators: Nahid Zaman, PharmD Candidate, SUNY Buffalo and
Md. Ehtesham Reza; Formulation Scientist, Emcure Pharmaceuticals.
Afternoon Refreshment and Networking (Poster Viewing)
General Business Meeting: “AABPS – Achievements and Future Directions”
Mohammad Hossain, PhD, Muhammad Delwar Hussain, PhD and Zahur Islam, PhD
Awards & Recognitions
Muhammad Jamil Habib, PhD, Muhammad Delwar Hussain, PhD and
3:30 PM – 3:45 PM
3:45 PM – 4:45 PM
4:45 PM – 5:00 PM
Moderators of Each Focus Group
Mohammad Hossain, PhD
5:00 pm – 5:10 PM Closing Remarks
EVENING SESSION
Ballroom 5: “This Moment is Ours - with Family and Friends”
6:00 PM – 7:00 PM 7:00 PM –10:30 PM
Muhammad Delwar Hussain, PhD
Dinner
Cultural Program
Songs and cultural performances by :
Shikha Rouf, Sarah Naz Billah, Farhana Meer, Mohammad Mahbubul Haque & Sribash Dey
Comedy by: Shamim Ahmed, PhD, MBA
Emcees: Mohammad M. Haque and Rajib K. Paul, PhD
10
Convention Speakers
CONVENTION
Mollick Mahmood Hossain, M.Pharm
Managing Director, Novelta Bestway Pharmaceuticals Ltd.
Abstract: Bangladesh has all the potential to become world’s generic pharmaceutical product
manufacturing hub such as it is for RMGs. With a population of 156.66 million, the country’s
social development indicators are very promising. Bangladesh is enjoying a consistent GDP growth
around 6.50% over last 10 years. Significant progress has been made in areas like Annual GDP
growth, Per capita GDP, Population growth, Literacy rate etc. The trade deficit of the country
is also coming down. Renowned Investment analysts like JP Morgan, Goldman Sachs, investor
Chronicle has highly rated Bangladesh as an attractive investment destination.
Pharmaceutical industry is one of the fastest growing business sectors in Bangladesh. Local market
is about USD 1.51 Billion and it is the second highest contributor to national exchequer with the largest white color
employment sector. Local companies largely dominate the market and the industry is almost self sufficient to meet
the domestic demand. Moreover, Bangladesh is also exporting to 90 countries with a growth rate of 25%. Many local
companies have achieved international regulatory certifications like TGA, UKMHRA, GCC, AGES, ANVISA, EUGMP. At least 3 local companies are in the final stage of US-FDA approval. Within next couple of years, Bangladesh
Pharmaceutical industry will become stronger and play a major role in global generic market with a size of around
USD 300 Billion with a CAGR of 9.7%. Asian countries like India and China are the major players in global generic
and Bangladesh has all the potentials to be one of them. In last 5 years, modern, sophisticated and complaint facilities
are established. The country is now producing high-tech products like biosimilars, prefilled syringe, Freeze-Dried,
MDI, Hormone & steroid products. With world-class pharmaceutical production facilities, low overhead and business
cost compared to other regional players like China, India, and Korea, Bangladesh is definitely an attractive destination
that can be utilized as an emerging global generic HUB.
Bio Profile: Mollick Mahmood Hossain completed B. Pharm (Hons) and M. Pharm from the Faculty of
Pharmacy, University of Dhaka. He is the Co-founder and Managing Director of NOVELTA BESTWAY
PHARMACEUTICALS LTD (NBPL). Mollick is a renowned professional with 23 years of working experience in
different reputed Pharmaceutical companies like BEXIMCO Pharmaceuticals Ltd. INCEPTA Pharmaceuticals Ltd.
& SILVA Pharmaceuticals Ltd. In his career, he held many vital positions like Marketing Executive, Sales Manager,
Marketing Manager, Marketing Director, and Head of International Marketing to Head of operation. As a Pharmacist
Mollick visited more than twenty countries. Because of his contribution to pharmaceutical sector, the Govt. of
Peoples Republic of Bangladesh has appointed Mollick Mahmood as a board member of Bangladesh Council of
Scientific & Industrial Research (BCSIR), the only government KPI R&D institute. He is very much involved in to
equip the country people for proper employment in his home district Faridpur for last12 years.
Shahid Rahman
Abstract: With few exceptions most immigrants assimilate into the their host country, within one
hundred years. Inspiring South Asian Youth’s (I-SAY) aim has been to create an alternative
integration model by which future and current generations can remain successful as Americans
(educated and civic minded), while retaining portions of their cultural identity. I-SAY’s model
aims to utilize and mobilize youth in creating solutions to local issues that are both creative and
attractive to other youth. The integration model is replicable and scalable.
Bio Profile: The Founder and President of I-SAY (www.isay.org) has extensive experience in the
non-profit sector related to the integration of South Asians in the United States. He has chaired,
organized and spoke about many issues related to South Asians in the United States. He is also the
President of Bangladeshi American Youth Association and is a graduate of Rutgers University with
a degree in finance.
11
Convention Speakers
Fabio Benedetti, MD
Chief Medical Officer & Senior Vice President, Taiho Oncology, Inc., Princeton, New Jesrsey, USA
TAS-102: A case study in the Phase I through III clinical development of an anti-cancer
compound.
Abstract: TAS-102 is an oral combination drug of trifluridine, an antineoplastic nucleoside analog,
which is incorporated directly into DNA and tipiracil hydrochloride, an inhibitor of the FTDdegrading enzyme, thymidine phosphorylase, which helps maintain effective concentrations of
FTD in the blood. A historical review of the clinical trial rationale, design and findings at each
phase of clinical development of this compound will highlight key principles and concepts in
oncology drug development.
Bio Profile: Dr. Fabio Benedetti, MD, was appointed Taiho Oncology, Inc’s Senior Vice President
and Chief Medical Officer in March 2010. Dr. Benedetti has extensive experience in oncology,
ranging from medical practice to clinical drug development and medical affairs. Prior to joining the
company, he has served in various leadership positions including Senior Vice President and Chief
Medical Officer of Oncology at Geron Corporation, Vice President of Medical Affairs at Onyx
as well as Millennium Pharmaceuticals, and has held Medical Director level positions at BristolMyers Squibb and Roche Laboratories. Dr. Benedetti graduated from Brown University, where he
also went on to receive his medical degree in 1990. After finishing his Internal Medicine residency
at Strong-Memorial Hospital in Rochester, NY, he went on to complete a Medical Oncology/
Hematology fellowship at the Memorial Sloan-Kettering Cancer Center in New York City, where
he subsequently worked as an Attending Physician for the Gastrointestinal Oncology Service.
Tapan Chowdhury
Managing Director, Square Pharmaceuticals Ltd., Bangladesh
Abstract: Not submitted.
Bio Profile: Mr. Tapan Chowdhury, a leading industrialist of Bangladesh started his career in 1978
as a Marketing Officer in their family business Square Pharmaceuticals Ltd a private limited
company. Today he is the Managing Director of Square Pharmaceutical, Square Textiles, Square
Hospitals Ltd & few other companies of Square Group. He along with his late father Mr. Samson
H Chowdhury, founder Chairman of Square Group, took Square Pharmaceuticals Ltd for Public
Listing around 20 years back. Mr. Chowdhury is a Science Graduate from Dhaka University & Has
a post graduation degree in Marketing from U.K. He is the President of Bangladesh Publicly Listed
Companies (BAPLC), President Bangladesh Employers Federation (BEA) Incoming President of
Bangladesh Textile Mills Association (BTMA ) Mr. Chowdhury is in the Board of Governors of
Bangladesh Enterprise Institute (BEI). He also served as an Adviser (Minister) to the Government
of Bangladesh during the last Caretaker Government & was responsible for five ministries
including Power, Energy, Food & Disaster Management, Science & ICT & Youth & Sports. Mr.
Chowdhury is involved with number of social & philanthropic organization.
12
CONVENTION
Convention Speakers
Mahmudul Khan, PhD
Novartis Pharmaceuticals
Applications of Statistical Concepts in Pharmaceutical Sciences
Abstract: The purpose of this talk is to present applications of commonly used statistical methods,
as encountered in the pharmaceutical industry. It includes types of data and their tabular and
graphical representations. Application of confidence intervals and tests of hypothesis are also
presented.
Bio Profile: Dr. Mahmudul Khan obtained his BS and MS in Statistics from the University of Dhaka
and then pursued his Ph.D. in Biostatistics from the University of Hawaii (supported by East West
Center scholarship). He taught Statistics at the University of Dhaka, Jahangirnagar University
and North South University at the undergraduate and graduate levels Dr. Khan imparted and
continue to impart training, on statistics, in Bangladesh and in the US. He has been working in
the Pharmaceutical industry in the US for the past 15 years, including J&J, Novartis, Biogen and
Abbott. His hobbies include following cricket and soccer.
Ahmad Abdullah, M.Pharm
Proprietor, Shoppers Drug Mart, Scarborough, Ontario
Challenges and opportunities in the profession of pharmacy in canada
Abstract: This presentation will provide a brief overview of changes in the economic picture and
government regulations which changed the landscape of pharmacy practice in Canada over the last
decade. Specifically, it will discuss the impact of Bill 102 and the economic recession in the years
2008-2009 on the pharmacy profession. Some of the challenges that these changes have posed
include closure of pharmacy business, reduction of hours of operation in pharmacies, withdrawal
of funds for interns and students, increased number of pharmacists with a decrease in the number
of jobs. Bill 102 in Ontario and similar steps taken by other provinces have negatively impacted
brand manufacturing due to generic policies by the government of Canada. Other challenges
include a lost revenue of 809 million dollars for the brand manufacturer, lay offs and hiring freeze
for multinational companies in Canada. Introduction of registered pharmacy technicians with
more responsibilities have negatively impacted pharmacist job prospects. Opportunities brought
by the changes include the expanded scope of pharmacy practice approved by the government,
introduction of paid services by the government (i.e. pharmaceutical opinion, medication review
and injection services, more availability of support by other health care professionals of different
ethnic backgrounds in order to expand collaborative pharmacy business, more job opportunities in
generic manufacturer companies, stronger professional associations to provide a broader platform
for professional advancement.
Bio Profile: Ahmad Abdullah obtained his Bachelor of Pharmacy degree in 1975 and Masters in
Pharmacy in 1977 from the University of Dhaka, Bangladesh. He immigrated to Canada in 1998.
He obtained his license to practice Pharmacy in Canada in 2000. He served as a Manager of WalMart Pharmacy from 2001 to 2007. He is currently Pharmacist Owner at Shoppers Drug Mart
in Scarborough, Ontario. He also works as a teaching associate to train fourth year Pharmacy
Students of the University of Toronto seeking practical experience.
13
Convention Speakers
Arshad Jamil, MS
Senior Scientist, Emcure Pharmaceuticals, NJ
Mass Spectroscopy as a Detection Technique Gaining Popularity in Analytical Assessment
Abstract: HPLC Science has always been moving to more specific and more sensitive detection
modes and this is where Mass Spectroscopy has become the most sought after detection Tool in
Analytical Assessment. The combination of High-Performance Liquid Chromatography (HPLC)
and mass spectrometry (MS) offers the analytical chemist one of the most powerful analytical
techniques of modern times - it is the present and the future. LCMS is spreading widely through
pharmaceutical, environmental, food, industrial materials and other fields. Mass Spectroscopy is an
analytical technique used to measure the mass-to-charge ratio of ions. MS holds its popularity due
to High sensitivity, High Specificity due to specific fragmentation pattern of ions and High Resolution of time. The challenge in MS
is to eliminate the solvent while maintaining adequate vacuum level and to generate gas phase ions. The large majority of application
in MS employs electrospray and atmospheric chemical ionization technique for the ionization and atmospheric photo ionization
technique is currently emerging. Triple Quadrupole Mass Spectrometry is the method of choice for accurate quantification and
confirmation of trace level analytes in complex Matrix. From the detection of drugs and metabolites in biological specimens,
environmental contaminants and pesticides in food, to leachables and extractables from closure and containers and packaging
systems and from in process manufacturing caveat, in Parenterals and Opthalmics, analyst all over the world are challenged with
detecting an increasing number of target analytes with greater sensitivity and in more samples than ever before. FDA regulations and
alertness with respect to safety of population have created more demand of MS with respect to analytical detection of the critical
entities.
Bio Profile: Arshad Jamil, M.S. is a Senior Research Scientist at Emcure Pharma in East Brunswick, NJ. In his role, Mr. Jamil focuses
on method development and validation and is also responsible for the company’s LCMS activity performing method validation
and tests for extractable and leachable components in injectables related to FDA queries and submissions. Mr. Jamil has more
than 25 years of experience in drug metabolism, pharmacokinetics, bio-analytical, and analytical research and development in both
brand and generic pharmaceutical industries. Prior to joining Emcure, Mr. Jamil served as a Senior Scientist at Sandoz, Inc. where
he was involved with the Formulation Support Group and was responsible for analytical method development and validation of
drug products on various analytical platforms including HPLC, UPLC, UPLC H-Class, GC, and UV. Earlier in his career, Mr.
Jamil worked at Wyeth-Ayerst Research, Inc. (now Pfizer) where he served as senior scientist in preclinical drug metabolism and
disposition research for the development of novel pharmaceutical compounds. Mr. Jamil has also worked at Barr Laboratories (now
Teva), and GoldPharm Research, Inc. in Analytical R&D. Mr. Jamil earned his B.Pharm and M.Pharm degrees from the University
of Dhaka, Department of Pharmacy and Later a M.S. from the Arnold Marie Schwartz College of Pharmacy with distinction from
the Rho Chi Honors Society.
(Biologics)
Muhammad Delwar Hussain, & Milad Khan, MS
GROUP
III (Clinical Research)
Jabed Seraj, MD, PhD & Mohammad Hossain, PhD
GROUP
Enamul Kabir, MS & Shah Rashid, MS
IV
V
GROUP
II
(Analytical and Formulation Development)
VI
GROUP
GROUP
I
GROUP
Focus Group Discussion Topics
(Pharmacy Practice)
Swapan Kumar Das, PharmD & Ahmad Abdullah, MPharm
(Regulatory Affairs)
Moderators: Naushad Islam, MS & Fakrul Sayeed, PhD
(Generic Product)
Moderators: Anwar Hossain, PhD & Sharif Ahmed, MS
CONVENTION
Articles
by the Members
15
Engineered Pulmonary Medicine and
Appropriate Drug Delivery Technology
Mohammed Ali Ph.D., MBA, CSMS.
Associate Professor, Department of Technology, Jackson State University, Jackson, MS 39217
The human lung is an effective route for non-invasive drug
delivery since it provides large surface area for rapid
absorption, minimal physical barrier, absence of extreme
pH and metabolism, no first pass liver, rich blood supply,
and poor bioavailability of oral drugs. The physical and
electrical properties of active pharmaceutical ingredient
(API) and excipient interactively influence five
electromechanical deposition mechanisms of respiratory
medicinal aerosols while flowing through the airways
including nose, mouth, pharynx, trachea, bronchi,
bronchioles and alveoli.
results using these modeling tools agreed with in-vitro study
results as well.
In the field of aerosol medicine there have been several
methods invented and marketed to improve pharmacokinetic
efficacy and effectiveness in respiratory drug delivery, and
to minimize losses in the delivery devices. Examples are:
nanoparticle therapeutics for reduced side effects and more
targeted deposition, salt-based formulations optimized for
inhalation to create a robust and flexible platform that can
accommodate low or high drug loads of a range of molecule
types, sustainable long pulmonary absorption achieved
through tissue binding and cellular uptake in the airways,
moderately lipophilic compounds with positive electrostatic
charge under physiological conditions to bind preferentially
lung tissues, liposomal encapsulation in controlled-release
particles, and increase the molecular
mass of the drug by conjugation
with a water-soluble inert ligand or
another protein.
The therapeutic particles from a specific device during the
inhalation process come out as an aerosolized form. The
dispersion of these pharmaceutical powders often face
difficulty since the fine powders are cohesive due to the strong
inter-particle adhesion forces: van
der Waals, capillary and electrostatic
attractions. Typically, cohesive forces
are proportional to the diameter d of
the particles, whereas, the detachment
forces for re-suspending the particles
forming aerosol is proportional to d2
when aerodynamic shear force is used
for the dispersion. Thus the smaller
More examples of improved drug
the diameter the higher is the shear
delivery methods may include the use
force needed for efficient dispersion
of a valve holding chamber or spacer
for forming aerosol containing the
for metered dose inhalers, inlet
primary API and excipient particles
design change of dry powder inhalers
micronized in the jet mill. A solution
for less resistance to air flow and
to these problems can be the Fig. 1. Respiratory therapeutic particle deposition
particle de-agglomeration, facemask
manufacturing of engineered API and mechanisms in the human lung.
with nebulizer and spacer for infants
excipient to manipulate the cohesivity,
and children, charge neutralization
and dispersability with necessary
of nebulized aerosol before administration, non-propellant
magnitudes of particle charge during the micronization
inhaler with soft mist of aqueous drug solution through a
process. These modifications will improve blending
set of fine channels in the nozzle, enhanced condensational
uniformity, and long term stability of the powder mixtures.
growth of submicron particle for minimum mouth-throat
The primary mechanisms of lung deposition of inhaled
respirable drug aerosol particles in the human lung consist
of the five electromechanical processes: impaction, diffusion,
interception, gravitational settling and electrostatic effects
as depicted in Fig.1. There are a number of mathematical
models and computational tools developed to understand
particle flow and predicting deposition patterns of particles
in the whole lung or its specific region. In-silico study
deposition, evaporation and condensation aerosol generator
for poorly water soluble drugs suitable for pulmonary route.
Studies with laboratory animals showed that antibiotic dose
of nanoaerosol generated by electrospray-neutralization
process for pulmonary drug delivery method requires one
sixth fraction of dose for peroral treatment.
The high flow nasal cannula (HFNC) therapy is currently
being employed to deliver oxygen to the patients with
AABPS Member’s Articles
16
CONVENTION
moderate levels of hypoxemic respiratory problems. In
the same fashion, this method can be used to deliver
drugs to the lungs. However, it was reported that infant,
pediatric and adult nasal cannula show a decrease in
delivery with the increase of inspiratory flow rate which
can be explained by the higher drug deposition (losses)
in the device components. These losses often occurs as a
result of combined effects of several issues such as inside
geometry of cannula, directional change of aerosol flow
in the nose, mouth, pharynx and trachea. However, the
enhanced condensational growth and excipient enhanced
growth showed substantial improvement (~80%) without
incorporating exhalation cycle. These results may prove
promising if the realistic inhalation-exhalation flows are
simulated.
References:
1. Ali M. Pulmonary drug delivery. In:
5. Asgharian B, Hofmann W, Bergmann 9. Onischuk AA, Tolstikova TG, Sorokina
Kulkarni K. Handbook of non-invasive
R. Particle deposition in a multipleIV, Zhukova NA, Baklanov AM,
drug delivery systems, 1st edition.
path model of the human lung. Aerosol
Karasev VV et al. Anti-inflamtory
Amsterdam, The Netherlands: Elsevier
Sci Technol 2001;34:332-339.
effect from indomethcin nanoparticles
Inc; 2009:209-246.
inhaled by male mice. J Aerosol Med
6. Cheng YS. Mechanisms of
Pulm Drug Deliv 2008;21(3):231-243.
2. International Commission on
pharmaceutical aerosol deposition in
Radiological Protection Publication
the respiratory tract. AAPS Pharm Sci 10. Gulshahi L, Tian G, Azimi M, Son
66; Human respiratory tract model for
Tech 2014;15(3):630-640.
YJ, Walenga R, Longest PW, Hindle
radiological protection, New York, NY:
M. The use of condensational growth
7. Patton JS, Byron PR. Inhaling
Elsevier; 1994.
methods for efficient drug delivery
medicines: delivering drugs to the body
to the lungs during noninvasive
3. Martonen T, Fleming J, Schroeter J,
through the lungs. Nature Rev Drug
ventilation high flow therapy. Phar Res
Conway J, Hwang D. In-silico modeling
Discov 2007;6:67-74.
2013;30(11):2917-2930.
of asthma. Drug Del Rev 2003;55:8298. Davis ME, Chen ZG, Shin DM.
845.
11. Dhand R. Aerosol therapy in patients
Nanoparticle therapeutics: an emerging
receiving noninvasive positive pressure
4. Ali M, Reddy RN, Mazumder MK.
treatment modality for cancer. Nat Rev
ventilation. J Aerosol Med Pulm Drug
Electrostatic Charge Effect on
Drug Discov 2008;7:771-782.
Deliv 2012;25(2):63-78.
Respirable Aerosol Particle Deposition
in a Cadaver Based Throat Cast
Replica; J Electrostat 2008;66:401-406.
NOTE: This article is part of the paper published in the Respiratory Care Journal.
AABPS Member’s Articles
17
Immunomodulatory receptor (IMR) engagement –
breakthrough in cancer treatment
Shuangping Shi and Mohammed Shameem
Biologics Bioprocess Development, Merck Research Laboratories, NJ, USA
The recent cancer immunotherapy-resurgence, and inhibitory signals fine-tunes the extent of T-cell
especially T-lymphocyte (T-cell) mediated therapies,
activation, host defense, and “self-tolerance”.
has set the stage for a revolutionary-change in cancer
treatment using monoclonal antibody based therapies.
Unlike traditional immunotherapy agents (e.g. Antibodies for targeting IMRs
Herceptin® and Retuxin®) which target specific epitopes Monoclonal antibodies have become powerful weapons
on cancer cells, T-cell mediated immunotherapies for targeting IMRs on T-cells for cancer immunity. The
structural complexity of antibody CDRs allows high
target
surface
expressed-immnunomodulatory
receptors (IMRs) on T-cells (activated and regulatory). degree of specificity for target engagement, sparing
Physiologically, IMRs can act either as inhibitory- the host from off-target side effects. In antagonistic
fashion, the high affinity of an
immune checkpoints, as in the
antibody to target, often stronger
maintenance of “self-tolerance”
than IMRs’ natural ligands, give
(e.g. CTLA-4, PD-1, LAG-3, TIMrise to potential advantages in
3, BTLA, and TIGIT), or in a
completive binding to IMRs
concerted co-stimulatory fashionpreventing
ligand-induced
as in the case of potentiated T-cell
receptor
activation.
Conversely,
activation (e.g. OX40, GITR, CD27,
as
an
agonist,
conformational
4-1BB, and ICOS) (ref 1). Preantibodies can activate a coclinical and clinical studies have
stimulatory IMR in the absence
validated the effectiveness of IMRs
of its natural ligand.
as therapeutic targets showing that
blockade of inhibitory-or activation
Monoclonal antibodies are highly
of co-stimulatory IMRs can boost
tolerated by human body with
immune responses against cancer.
a long half-life and predictable
Targeting these IMRs on T-cells Adopted from Mellman et al (ref 1)
pharmacological
properties.
and combining these strategies
Over
a
quarter
century
of proven
with other therapeutic approaches
industrial
record
and
regulatory
experience
makes
are anticipated to transform cancer from a lethal
these classes of molecules the best platform of choice
disease to a chronic- more manageable condition.
for T-cell mediated immunotherapies.
T-cell activation and cell death
Effective activation of T-cells requires two sets of signals.
The first signal is delivered through the interaction
between the T-cell receptor (TCR), which is the
primary stimulatory receptor, and the antigen bound
major histocompatibility complex (MHC) on antigen
presenting cells (APCs). The second signal occurs
when the B7.1 and B7.2-ligands on APCs interact
with the co-stimluatory-CD28 receptor on T-cells.
Upon T-cell activation, inhibitory IMRs are induced
and trigger “negative” signals that dampen activation.
At the same time, co-stimulatory IMRs are induced
to prolong T-cell activation and prevent programmed
cell death. The equilibrium between co-stimulatory-
Antagonists of inhibitory IMRs
Two of the best studied inhibitory-immune checkpoints
are Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4)
and Program Death 1 (PD1). CTLA-4 is a cell surface
molecule that is closely related to CD28, which is
expressed constitutively on T-cells and provides the
major co-stimulatory signal for T-cell activation. In
contrast, CTLA-4 is transiently expressed following
T-cell activation and competes with CD28 for their
shared ligands B7.1 and B7.2. The competition between
CD28 and CTLA-4 for B7.1 and B7.2 inhibits excessive
T-cell activation through CD28 (ref 2). PD1 is another
inhibitory IMR molecule that is expressed after T-cell
activation. PD1 has two ligands, PDL1 and PDL2, both
AABPS Member’s Articles
18
CONVENTION
are B7 homologues. The interaction of PD1 with its
ligands PD-L1 and PD-L2 dramatically inhibits T-cell
proliferation and cytokine secretion (ref 3).
It is hypothesized that cancer cells may be able to “highjack” these immune checkpoint IMRs to escape from
host immune responses. By therapeutically blocking
(antagonizing) the immune checkpoints or inhibitory
IMRs, the “brake-signal” is essentially taken off the
T-cell which then allows the immune system to mount
a durable response to cancer cells.
This theoretical-prolonged immune response has
the potential to allow high rates of sustained tumor
regression, and in-practice checkpoint-blocking
antibodies such as anti-CTLA-4 (BMS Yervoy®
or ipilimumab), anti-PD1 (Merck MK-3475 or
pembrolizumab and BMS nivolumab) and anti-PDL1
(Roche RG7446 and Astrazeneca MEDI-4736) have
demonstrated impressive clinical benefits and longterm survival in terminally ill cancer patients. In clinical
studies for melanoma patients, one year survival rates
for Yervoy®, MK-3475, and nivolumab were 46%, 69%,
and 62%, respectively. Concurrent treatment with
Yervoy and nivolumab resulted in a 1-year survival rate
of 85% and 2-year survival rate of 79%. However the
higher response rate is accompanied with increased
toxicity (autoimmunity) compared to therapy with
either single agent.
Another interesting immune checkpoint inhibitor
in clinical development is anti-LAG-3 (BMS BMS986016). Lymphocyte Activation Gene 3 (LAG-3) is
expressed on T-cells and Natural Killer (NK) cells.
Binding of LAG-3 to the MHC Class II complex on
APCs blocks proliferation and effector functions of
T-cells. In pre-clinical models, anti-LAG-3 worked
synergistically with anti-PD1 curing mice of established
tumors that were largely resistant to single antibody
treatment (ref 4).
Agonists of inhibitory IMRs
functions upon activation (ref 5). OX40 also shuts
down immunosuppressive regulatory T-cells (Treg) in
tumors. The dual role makes OX40 an attractive target
for cancer immunotherapy. AstraZeneca is evaluating
a mouse monoclonal antibody-anti-OX40 in a Phase
1 trial. The molecule elicited tumor regression and
showed increased T-cell/B-cell responses to reporter
antigen immunizations (ref 6).
The TNF receptor super family members 4-1BB
and (Glucocorticoid-Induced TNFR family Related
gene) GITR are also being investigated as cancer
immunotherapeutic targets. 4-1BB is expressed on
activated T-cells. An “agonist-acting” (functional
accelerator)-anti-4-1BB antibody induces CD8+Tcell activation and interferon gamma secretion.
Currently two 4-1BB agonist antibodies (BMS BMS663513 and Pfizer PF-05082566B) are under clinical
evaluation for solid tumor and B-cell lymphoma. GITR
is expressed at a significantly higher level on tumorinfiltrating Treg cells. Anti-GITR antibody was shown
to promote effector activation and Treg cell depletion
or inactivation at the tumor site (ref 7). TRX518 and
MK-4166 are two agonist anti-GITR antibodies under
early clinical development by GITR Inc. and Merck,
respectively.
Another stimulatory IMR worth mentioning is CD27.
Unlike other TNF receptor super family members
mentioned above, CD27 is constitutively expressed
on naive and activated T-cells. CD27 is known to
be involved in T-cell activation, effector function,
maturation, and survival (ref 8). There is one antiCD27 agonist antibody (Celldex CDX-1127) in Phase
1 development for the treatment of B-cell hematologic
malignancies and solid tumors. In pre-clinical studies,
this antibody induces T-cell activation and tumor
immunity (ref 9).
Conclusions
Despite the benefits that come with transforming
cancer therapy, IMR-targeting agents do carry the
risk of autoimmune disease. The CTLA-4-blocking
Yervoy has been found to cause colitis, hepatitis, toxic
epidermal necrolysis, pituitary inflammation, etc. and
TGN1412, a CD28 agonist, caused life-threatening
autoimmune reactions in healthy volunteers in a phase
1 study (ref 10). Nonetheless, the combination therapy
that results from eliminating immune checkpoints and
stimulating a positive immune response to the tumor,
in conjuction with other cancer therapies, is anticipated
to ultimately lead to cancer cure.
As mentioned, immune checkpoints are often
described as the “brake” for host immune responses.
Sometimes mounting a robust and persistent immune
response to cancer cells not only requires one to lift
the “brake”, but also to push the “accelerator”—costimulatory IMRs. A number of co-stimulatory IMRs,
most of which belong to the tumor necrosis factor
(TNF) receptor family, have been-and are currently
being-investigated in clinical studies. OX40, a member
of TNF receptor family expressed on the surface of
activated T-cells, boosts T-cell division and survival, in
addition to stimulating immune effector and memory
AABPS Member’s Articles
19
References and Suggested Reading
1. Mellman I, Coukos G & Dranoff G.
4. Woo ST, et al. Immune inhibitory
7.
Cancer immunotherapy comes of age.
molecules LAG-3 and PD-1
Nature (2011) 480 (7378): 480-9.
synergistically regulate T-cell function
2. McCoy KD and Le Gros G. The role
to promote tumoral immune escape.
of CTLA-4 in the regulation of T cell
Cancer Res. (2012) 72(4):917-27.
immune responses. Immunol Cell Biol. 5. Croft M. Control of immunity by
8.
(1999) 77(1):1-10.
the TNFR-related molecule OX40
3. Keir ME, Butte MJ, Freeman GJ,
(CD134). Annu. Rev. Immunol. (2010)
Sharpe AH. PD-1 and its ligands in
28: 57–78.
tolerance and immunity. Annu Rev
6. Curti BD, et al. OX40 is a potent
Immunol. (2008) 26:677-704.
immune-stimulating target in late9.
stage cancer patients. Cancer Res.
(2013) 73(24):7189-98.
Bulliard Y, et al. Activating Fc γ
receptors contribute to the antitumor
activities of immunoregulatory
receptor-targeting antibodies. J Exp.
Med. (2013) 210 (9): 1685-93.
Hendriks J, et al. CD27 promotes
survival of activated T cells and
complements CD28 in generation and
establishment of the effector T cell
pool. J. Exp. Med. (2003) 198: 1369-80.
He JZ, et al. Agonist anti-human
CD27 monoclonal antibody induces
T cell activation and tumor immunity
in human CD27-transgenic mice. J
Immunol. (2013) 191(8):4174-83.
10. Sheridan C. TeGenero fiasco prompts
regulatory rethink. Nat. Biotechnol.
(2006) 24: 475–6.
AABPS Member’s Articles
Cultural Performers
Shikha Rouf
Shikha Rouf started her musical journey at a very early age of 8 with Ustad Zakir Hussain,
father-in-law of the famous Niaz Mohammad Chowdhury. Five years of “Chhayanot” gave
her formal lessons in Nazrul Geeti, an eastern classical base and many awards. She is also a
former champion of DUCSU and “Shamsunnahar Hal” in music. Soon her achievements
opened the doors in the media; she was enlisted as a grade “A” artist in both National
TV and Radio. Shikha’s passion for singing made her a very popular name in the cultural
shows of Dhaka, both in public and private aspects. And now she has carried her musical
ventures to Toronto, and continues to perform today.
Mahbubul Haque
Mahbub started taking music lessons at the age of five from renowned teachers and graduated in Tagore Songs/Semi Classical from Shangeet Bhaban under the direct mentorship
of Late Ustad Kalim Sharafi. In the last 20 years, he has played, performed and recorded
albums with accomplished bands namely The Trap, Faith, Pentagon, Warfaze, Ark, Winning,
Jahmalama (Canada), and composed original music for various artists from all over the world
including Bangladeshi top celebrities. Currently Mahbub is primarily focused on fusion projects for revitalizing Bangladeshi rare root music with the blend of world music for making it
more appeling to the new generation. He is also a subject matter expert in audiovisual pre/
post production technologies and event management.
Mahbub has graduated in Economics from the University of Toronto, works as a Senior
Business Analyst/Project Manager in the financial industry, and is happily married with
Asma Anjuman Ara with one daughter, Afsheen Haque.
Sarah Naz Billah
Sarah Naz Billah grew up in a family of talented musicians. Sarah started her classical music
lessons at the age of 5 years with Ustad Ali Imam and continued for 12 years under his guidance. After finishing college education and as a university student she joined “Chhayanot”,
where she trained in Nazrul Geeti and Lalon Geeti from renowned singer Farida Parvin.
She graduated with honors after five years of training at “Chayanaut” in Nazrul Geeti and
joined Chayanaut as a Nazrul Sangeet teacher. She won the Gold Medal at the National
Children Competition in 1989 and the National Education Week in 2001. As an enlisted
artist of Bangladesh TV, she also performed in Calcutta TV in 2006 and 2008. She was the
founding member of the band named, “Crimson” which was nominated as the “Best New
Band” at the Citicell Channel I Music Award in 2006. Sarah is a graduate of Jahangir Nagar
University with a major in English Literature. She completed a Diploma in Audio Engineering in Canada and is now working at “B4Ushowit.com” as an audio-visual technician. Her
performances aired in Toronto television and her numerous on-stage performances have
captivated audiences and helped her gain popularity at home and abroad.
Also, Farhana Meer & Sribash Dey
CONVENTION
20
Welcome
To the 2nd Annual
AABPS Convention
From your local
Bangladeshi-owned
Domino’s Pizza
Lumberton/Mt Holly 609-265-1300
Absecon 609-646-8808
Maple Shade 856-866-1500
Atco/Berlin 856-768-5522
Atlantic City 609-347-0303
Marlton 856-596-5900
Bayville 732-269-7800
Millville 856-327-4900
Brick 732-206-0002
Pennsauken 856-663-2522
Bridgeton 856-455-6800
Toms River 732-929-1818
Burlington 609-387-8400
Vineland 856794-3030
Camden 856-225-0400
Westmont 856-854-5600
Cape May Court House 609-465-9090 West Philadelphia 215-477-6000
Egg Harbor Township 609-646-8222
Williamstown 856-728-5533
Gibbstown 856-224-8700
Willingboro 609-871-8800
Glassboro 856-881-8100
Woodbury 856-845-6444
Hammonton 609-567-5111
Little Egg Harbor Township 609-296-2900
Call Salim Joarder, Owner, with any concerns
856-524-1200
AABPS 2014
CONVENTION
First Name
Ahmad
Sharif
Fakhruddin
Shamim
Mohammad
Muhammad
Mortuza
Prosenjit
Mohammad
Tapan
Swapan
Muhammad
Reza
Muhammed
Mohammad
Mollick
Saleh
Muhammad
Naushad
Mominul
Zahur
Rafiqul
Nasrin
Arshad
Enamul
Mohammed
Monzurul
Ashrafuzzaman
CONVENTION
List of Registrants
Middle
Last
Abdullah
Ahmed
Ahmed
Ahmed
S
Akbar
Amir
Ali
Bakshi
Chakraborty
A
Chowdhury
Chowdhury
Kumar
Das
Jamil
Habib
M
Haque
Anwar
Hossain
Hossain
Mahmood Hossain
Hussain
Delwar
Hussain
Islam
Islam
Islam
Islam
Jahan
Jamil
Kabir
Kabir
Kader
Khan
Shaheen
Milad
Mahmudul
Md Saifur
Mohammad
Abdullah
Md
Habib
Rajib
Ayaj
Shafiur
Md. Bodruddoza
Shaikh
Mamoon
Mehbuba
Shah
Md. Ehtesham
Abdus
Fakrul
Jabed
Syed
Mahiuddin
Nahid
Mohibuz
Mostofa
Gam
Huq
Rahman
Hasan
Al
K
Mukidur
S
Khan
Khan
Khan
Khan
Miah
Maruf
Muniruzzaman
Muntasir
Paul
Porosh
Rahman
Rafique
Rahman
Rashid
Rashid
Rashid
Reza
Salam
Sayeed
Seraj
Shahriyar
Talukdar
Zaman
Zaman
Zaman
Zamil
23
Dinner Buffet
ÆÆ
ÆÆ
ÆÆ
ÆÆ
Food Menu
Executive Continental Breakfast
ÆÆ
ÆÆ
ÆÆ
ÆÆ
Assorted Naan, Rolls & Butter
Mixed Field Greens tossed in a White Balsamic
Vinaigrette
Wild Mushroom stuffed Ravioli in Gorgonzola
Sauce
Grilled Halal Chicken Breast with a Lemon Herb
Sauce
ÆÆ
ÆÆ
ÆÆ
ÆÆ
ÆÆ
ÆÆ
Assorted Chilled Juices: Apple, Grapefruit,
Cranberry, Oranges Juices
Assorted Breakfast Bakeries
Whole Fresh Fruit
Coffee, Decaffeinated Coffee,
Tea
Saturday
Assorted Freshly Baked Cookies
Coffee, Decaffeinated Coffee, Tea
Assorted Sodas and Bottled Water
Millersport Delicatessen Lunch Buffet
ÆÆ
ÆÆ
ÆÆ
ÆÆ
ÆÆ
ÆÆ
Chef ’s Soup of the Day
Field Greens & Market Vegetables Tossed in a
Balsamic Vinaigrette
Tortellini Pasta Salad
Potato Chips & Pretzels
Roast Halal Beef, Tuna Salad, Seafood Salad
& Halal Chicken Salad
Sandwich Fixins
Array of Whole Fruit
Coffee, Decaffeinated Coffee, Tea
Assorted Sodas and Bottled Water
Dinner Buffet
ÆÆ
ÆÆ
ÆÆ
ÆÆ
Assorted Rolls and Butter
Strawberry Fields – Mixed Greens
tossed with Pecans, Gorgonzola, sliced
Strawberries served with Strawberry
White Balsamic Vinaigrette
Fresh Basil Tomato, Mozzarella and
Cucumber Salad with Balsamic Drizzle
Grilled Halal Chicken Breast with
Pineapple and Mango topped with Rock
Shrimp Relish
ÆÆ
ÆÆ
ÆÆ
ÆÆ
ÆÆ
Saturday
Cheddar & Swiss Cheeses, Julienne
Romaine, Sliced Tomatoes, Sliced Dill
Pickles
Appropriate Toppings & Condiments
Fresh Whole Wheat Rolls & Wraps,
Croissants & Assorted Deli Breads
Assorted Dessert Bars
Coffee, Decaffeinated Coffee, Tea and
Iced Tea
Saturday
Afternoon Break
ÆÆ
ÆÆ
ÆÆ
Cheese Pizzas
Stuffed Eggplant Rollatini in Tomato
Sauce
Rice with a Curry or Red Pepper Sauce
Chef ’s Choice of Vegetable
Plated & Served Chocolate Cake
Coffee, Decaffeinated Coffee, Assorted
Herbal Teas
Saturday
Mid-Morning Refresh
ÆÆ
ÆÆ
ÆÆ
Friday
ÆÆ
ÆÆ
ÆÆ
ÆÆ
ÆÆ
ÆÆ
ÆÆ
Saturday
Cajun Seared Salmon with Cucumber Yogurt
Oven Roasted Assorted Halal Chicken Pieces
Herb marinated coasted with Seasoned
Breadcrumbs
Pasta Marinara
Mashed Potatoes
White and Green Asparagus with Whole Roasted
Sweet Things
Carrot Cake
Freshly Brewed Coffee, Decaffeinated Coffee &
Herbal Teas